The aberrant expression of N-cadherin in epithelial cancer cells is a well-documented feature of epithelial malignancies, and an abnormal expression of N-cadherin has also been found in many other tumors, such as lung cancer, hepatic cancer, urothelial cancer, and prostate cancer, and is associated with disease progression [83,84,85,86]. Here, CDH2 is linked to prostate cancer.